What is SVA stock price today?

SVA (Sinovac Biotech Ltd) stock is trading at $6.47 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SVA stock going up or down today?

SVA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SVA stock now?

The decision to buy SVA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SVA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SVA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SVA stock overvalued or undervalued?

SVA currently trades at a P/E ratio of 6.66, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if SVA is fairly priced.

What is SVA's P/E ratio?

SVA has a price-to-earnings (P/E) ratio of 6.66, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is SVA's market cap?

SVA (Sinovac Biotech Ltd) has a market capitalization of $0.64 billion, making it a small-cap stock.

What is SVA's price to book ratio?

SVA trades at a price-to-book (P/B) ratio of 1.82, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does SVA pay dividends?

Yes, SVA pays dividends with a current yield of 8.50%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is SVA's dividend yield?

SVA's dividend yield is 8.50%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is SVA stock a good long-term investment?

SVA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is SVA's revenue growth rate?

SVA has shown revenue growth of 3.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, SVA is profitable with a profit margin of 0.2%. This indicates the company generates 0.2 cents of profit for every dollar of revenue.

What are the risks of investing in SVA?

Key risks for SVA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does SVA compare to its competitors?

Compare SVA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize SVA's performance and positioning.

What is SVA's stock price target for 2026?

Our AI model provides price targets for SVA based on fundamental analysis: Bull case $8.41 (+30%), Base case $7.44 (+15%), Bear case $5.82 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about SVA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for SVA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is SVA's next earnings report?

SVA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

SVA - Sinovac Biotech Ltd

NYSE * Health Care * Biotechnology

$6.47

+$0.00 (+0.00%)

About Sinovac Biotech Ltd

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

SVA Key Statistics

Market Cap

$642.44M

P/E Ratio

6.66

P/B Ratio

1.82

EPS

$0.97

Dividend Yield

8.50%

Revenue Growth

+3.0%

Profit Margin

0.2%

Employees

1,959

How SVA Compares to Peers

SVA has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

SVA has the fastest revenue growth among competitors

SVA is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
SVA(This stock)	$642.44M	6.7	3%	0.2%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Sinovac Biotech Ltd Company Information

Headquarters: China
Website: www.sinovacbio.com
Sector: Health Care
Industry: Biotechnology

About Sinovac Biotech Ltd

SVA Key Statistics

How SVA Compares to Peers

Sinovac Biotech Ltd Company Information

Upcoming Events for SVA